Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Equity Average (2020 - 2025)

Pulse Biosciences has reported Equity Average over the past 6 years, most recently at $98.6 million for Q3 2025.

  • Quarterly results put Equity Average at $98.6 million for Q3 2025, up 85.84% from a year ago — trailing twelve months through Sep 2025 was $98.6 million (up 85.84% YoY), and the annual figure for FY2024 was $79.6 million, up 278.09%.
  • Equity Average for Q3 2025 was $98.6 million at Pulse Biosciences, down from $111.5 million in the prior quarter.
  • Over the last five years, Equity Average for PLSE hit a ceiling of $116.7 million in Q1 2025 and a floor of -$6.5 million in Q1 2023.
  • Median Equity Average over the past 5 years was $40.3 million (2024), compared with a mean of $47.6 million.
  • Peak annual rise in Equity Average hit 2348.74% in 2023, while the deepest fall reached 119.82% in 2023.
  • Pulse Biosciences' Equity Average stood at $45.9 million in 2021, then plummeted by 95.7% to $2.0 million in 2022, then soared by 2348.74% to $48.3 million in 2023, then surged by 101.02% to $97.0 million in 2024, then rose by 1.64% to $98.6 million in 2025.
  • The last three reported values for Equity Average were $98.6 million (Q3 2025), $111.5 million (Q2 2025), and $116.7 million (Q1 2025) per Business Quant data.